Literature DB >> 1931474

1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.

D J Birkett1, J O Miners, R O Day.   

Abstract

The urinary 1-methyluric acid (1MU) to 1-methylxanthine (1MX) ratio has been assessed as a biochemical index of oxipurinol effect in vivo in man. Dosing with theophylline was used to produce 1MX as an intermediate metabolite in six healthy volunteers. A sigmoid Emax model was fitted to the data and gave a mean plasma oxipurinol IC50 of 3.0 +/- 1.1 mg l-1, a mean exponent n of 3.4 +/- 2.1 and a mean IC90 of 8.5 +/- 5.9 mg l-1. There was marked interindividual variability in the steepness of the plasma oxipurinol concentration response relationship, and in the plasma oxipurinol IC90 values. The study has confirmed the feasibility of using single doses of allopurinol to construct individual plasma oxipurinol concentration-response curves.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931474      PMCID: PMC1368450          DOI: 10.1111/j.1365-2125.1991.tb03888.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine.

Authors:  A Lelo; G Kjellen; D J Birkett; J O Miners
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

2.  Plasma oxipurinol concentrations during allopurinol therapy.

Authors:  B T Emmerson; R B Gordon; M Cross; D B Thomson
Journal:  Br J Rheumatol       Date:  1987-12

3.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors:  R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

Authors:  R O Day; J Miners; D J Birkett; G G Graham; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography.

Authors:  T Foenander; D J Birkett; J O Miners; L M Wing
Journal:  Clin Biochem       Date:  1980-06       Impact factor: 3.281

7.  Comparison of theophylline and theobromine metabolism in man.

Authors:  D J Birkett; R Dahlqvist; J O Miners; A Lelo; B Billing
Journal:  Drug Metab Dispos       Date:  1985 Nov-Dec       Impact factor: 3.922

8.  Effects of allopurinol on theophylline metabolism and clearance.

Authors:  J J Grygiel; L M Wing; J Farkas; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

9.  Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid.

Authors:  D J Birkett; J O Miners; J Attwood
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

  9 in total
  4 in total

Review 1.  New uses for allopurinol.

Authors:  R O Day; D J Birkett; M Hicks; J O Miners; G G Graham; P M Brooks
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

2.  A study on the route of 1-methylurate formation in theophylline metabolism.

Authors:  C Bayar; I Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

Review 3.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Direct conversion of theophylline to 3-methylxanthine by metabolically engineered E. coli.

Authors:  Khalid H R Algharrawi; Ryan M Summers; Sridhar Gopishetty; Mani Subramanian
Journal:  Microb Cell Fact       Date:  2015-12-21       Impact factor: 5.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.